Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune responses to Bexsero in healthy transgender and cisgender adults
2024-515599-11-00Phase 4Authorised
- Sponsor
- Ghent University
- Start
- Dec 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by Ghent University. Primary endpoints: Quantification of serum bactericidal antibody titers and Comparison of serum bactericidal antibody titers between groups. Planned start Dec 2024; status: authorised.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2024-515599-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515599-11-00.